Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice
Diabetic Medicine · 2026
DOI: 10.1111/dme.70232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Zhongpeng Qiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Liaoning Normal University, Dalian, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Atherosclerosis, Antimicrobial Peptides, Antimicrobial Cationic Peptides. Die Arbeit nennt 36 Literaturangaben. Gefördert von: the Young Science and Technology Star Program from Dalian Municipal Science and Technology Bureau, the Central Government-guided Local Scientific and Technological Development Fund from Dalian Municipal Science and Technology Bureau, Liaoning Normal University Scientific Research Project.
Abstract (Originalsprache)
Aims
Epidemiological evidence suggests that atherosclerosis (AS) may precede or coexist with type 2 diabetes mellitus (T2DM); however, whether anti‐atherosclerotic interventions can reduce T2DM risk remains unclear. Chensinin‐1b (C‐1b), an antimicrobial peptide derived from the skin secretions of Rana chensinensis , has previously demonstrated anti‐atherosclerotic activity, suggesting a potential therapeutic effect against T2DM in the context of AS.
Methods
In an apolipoprotein E‐knockout ( ApoE −/− ) mice model induced by high−fat diet (HFD), the developed process of pathological changes and inflammatory levels of pancreas and aorta were detected at early, middle and late stage of AS, meanwhile the anti−atherosclerotic and anti−diabetic effects of chensinin−1b were investigated.
Results
In the early and middle stages of AS (6−10 weeks), mice fasting blood glucose (FBG) did not change, but atherosclerotic symptoms were significantly exhibited, such as the increased pro−inflammatory factors levels, aortic plaque and blood lipid levels. During the late stage of AS (14 weeks), it was found that the FBG of ApoE −/− mice increased significantly, the pancreas was damaged, the insulin and blood lipid levels were unbalanced, and T2DM symptoms appeared. Treatment with chensinin−1b alleviated the progression of both AS and T2DM, particularly when it was administered in the early stage of the disease.
Conclusions
In ApoE −/− mice, prolonged atherosclerotic pathology is associated with T2DM development. The antimicrobial peptide chensinin−1b attenuates AS and improves metabolic parameters, indicating potential multitarget intervention capabilities. These findings identify chensinin−1b as a candidate molecule for preventing AS−related metabolic abnormalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science, Liaoning Normal University, Dalian, China.
- Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China.
ORCID-Profile: Dejing Shang
Förderung
- the Young Science and Technology Star Program from Dalian Municipal Science and Technology Bureau
- the Central Government-guided Local Scientific and Technological Development Fund from Dalian Municipal Science and Technology Bureau
- Liaoning Normal University Scientific Research Project
- National Natural Science Foundation of China
Zitieren
APA
Qiu, Z., Fan, F., Li, Z., Sun, Y., & Shang, D. (2026). Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice. Diabetic Medicine. https://doi.org/10.1111/dme.70232
Vancouver
Qiu Z, Fan F, Li Z, Sun Y, Shang D. Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice. Diabetic Medicine. 2026. doi:10.1111/dme.70232
BibTeX
@article{Qiu2026,
author = {Qiu, Zhongpeng and Fan, Fan and Li, Zhenjia and Sun, Yue and Shang, Dejing},
title = {Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70232}
}
EUVIMED